CRSP Stock Overview
A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
CRISPR Therapeutics AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$48.18 |
52 Week High | US$91.10 |
52 Week Low | US$37.55 |
Beta | 1.67 |
11 Month Change | -3.62% |
3 Month Change | -14.33% |
1 Year Change | 5.91% |
33 Year Change | -58.62% |
5 Year Change | 13.74% |
Change since IPO | 241.94% |
Recent News & Updates
Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Sep 13Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Sep 04Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Recent updates
Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Sep 13Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Sep 04Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Crispr Therapeutics: Beaten Down But Not Broken
Jul 07CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)
Aug 25Shareholder Returns
CRSP | US Biotechs | US Market | |
---|---|---|---|
7D | -1.6% | -1.3% | 1.6% |
1Y | 5.9% | 22.5% | 30.5% |
Return vs Industry: CRSP underperformed the US Biotechs industry which returned 22.5% over the past year.
Return vs Market: CRSP underperformed the US Market which returned 30.5% over the past year.
Price Volatility
CRSP volatility | |
---|---|
CRSP Average Weekly Movement | 7.0% |
Biotechs Industry Average Movement | 10.2% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRSP's share price has been volatile over the past 3 months.
Volatility Over Time: CRSP's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 407 | Sam Kulkarni | www.crisprtx.com |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.
CRISPR Therapeutics AG Fundamentals Summary
CRSP fundamental statistics | |
---|---|
Market cap | US$4.38b |
Earnings (TTM) | -US$265.80m |
Revenue (TTM) | US$202.23m |
21.1x
P/S Ratio-16.0x
P/E RatioIs CRSP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRSP income statement (TTM) | |
---|---|
Revenue | US$202.23m |
Cost of Revenue | US$484.70m |
Gross Profit | -US$282.47m |
Other Expenses | -US$16.67m |
Earnings | -US$265.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.00 |
Gross Margin | -139.68% |
Net Profit Margin | -131.44% |
Debt/Equity Ratio | 0% |
How did CRSP perform over the long term?
See historical performance and comparison